NASDAQ:TLSI TriSalus Life Sciences Q2 2026 Earnings Report $4.24 -0.10 (-2.30%) Closing price 04:00 PM EasternExtended Trading$4.24 0.00 (-0.12%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast TriSalus Life Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.16Beat/MissN/AOne Year Ago EPSN/ATriSalus Life Sciences Revenue ResultsActual RevenueN/AExpected Revenue$10.27 millionBeat/MissN/AYoY Revenue GrowthN/ATriSalus Life Sciences Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile TriSalus Life Sciences Earnings HeadlinesTriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference CallJuly 16, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 25, 2026 | prnewswire.comNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. Marjorie Taylor Greene claims the bill contains 'the entire setup, groundwork and infrastructure to move from cash to digital currency.' If the legislation becomes law, the implications for how Americans store and control their money could be significant. There may be a limited window to act before it takes effect.July 22 at 1:00 AM | Goldco Direct, LLC (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 23, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TriSalus Life Sciences Inc. - TLSIJune 18, 2026 | prnewswire.comTLSI Investors Have Opportunity to Join TriSalus Life Sciences, Inc. Fraud Investigation with the Schall Law FirmJune 17, 2026 | globenewswire.comSee More TriSalus Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TriSalus Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TriSalus Life Sciences and other key companies, straight to your email. Email Address About TriSalus Life SciencesTriSalus Life Sciences (NASDAQ:TLSI) is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs. The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings. Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.View TriSalus Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Apple Could Be the Last One Standing in the Tech Wreck3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Texas Power Play: Hut 8 Sparks a $9.8B AI Infrastructure DealMoog Is More Than a Missile Maker, and Wall Street Is NoticingAlphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds Build Upcoming Earnings RTX (7/23/2026)Lockheed Martin (7/23/2026)Newmont (7/23/2026)Intel (7/23/2026)Nokia (7/23/2026)Relx (7/23/2026)SAP (7/23/2026)STMicroelectronics (7/23/2026)T-Mobile US (7/23/2026)Comfort Systems USA (7/23/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
